Primarily focusing on oncology, the peer-reviewed journal Oncotarget also publishes work in the aging, immunology, microbiology, autophagy and cell death fields. Research papers receive a timely and unbiased peer review; Oncotarget also accepts reviews, case reports, editorials and news.
Oncotarget publishes under a Creative Commons Attribution License, where the researcher’s contribution to cancer research is recognized by redistribution, reuse and frequent citations of his or her paper worldwide. Free, unrestricted access to papers published on Oncotarget allows for global dissemination of exceptional discoveries, providing valuable cancer research information to any individual interested in oncology. Authors also receive additional exposure through Oncotarget’s Facebook page, which includes the latest featured cover article and interviews with authors. Links to the latest issues of the journal are also on Oncotarget’s LinkedIn page.
As a bi-weekly online medical journal, Oncotarget that strives to publish scientific results as rapidly as possible after the stringent peer-review process. Oncotarget’s rapid peer-review follows the highest standards; editors, and reviewers follow CMJE’s Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and the COPE Code of Conduct and Best Practice Guidelines for Journal Editors. Download output styles at Endnote.com.
Andrei V. Gudkov and Mikhail V. Blagosklonny of the Roswell Park Cancer Institute are the journal’s editors-in-chief. Dr. Blagosklonny is the editor-in-chief of Cell Cycle and one of the co-founders of Aging, Oncotarget and Oncoscience as well.
Oncotarget is published by Impact Journals, which also publishes Aging, Oncoscience and Genes & Cancer. Started in 2010, the number of papers published by Oncotarget radically increased, making it one of the top oncology journals today. Oncotarget is also available on Dove Press.